Lymphoseek tilmanocept regulatory update

FDA extended the PDUFA date by 90 days for diagnostic product Lymphoseek tilmanocept from Navidea (formerly Neoprobe Corp.) to Sept. 10 from June 10. The NDA is under review for use in intraoperative...